417
PYC is using its expertise in RNA drug design and proprietary drug delivery technology to bring a powerful new class of precision medicine to patients. With an initial focus on rare eye disease, PYC’s technology has the potential to unlock treatments for multiple types of genetic disease.
The company has proven the efficacy and safety of its lead drug program in patient-derived models and has launched formal studies in preparation for human clinical trials in 2021.
